RxDoctor Payments Data

Shantha Kumar, MD

Cardiovascular Disease · Apache Junction, AZNPI 1396768958

Payments from drug & device makers

$5,881in general payments, 2019–2025

Across 198 payments — averaging $29.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Abbott$658
  • Boston Scientific$590
  • GE HealthCare$364
  • Abiomed$221
  • Novartis$124
  • plus $532 from 16 others

What the payments were for

  • Travel & lodging$2,27039%
  • Food & beverage$3,51160%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,881 in reported general payments places this provider in the 65th percentile of 423 cardiovascular disease providers in Arizona.

See all cardiovascular disease providers in Arizona

Medicare billing

Part B allowed, 2024
$1,234,034
Medicare patients
763
Services billed
9,355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban296$366,343
EntrestoSacubitril/Valsartan88$110,298
XareltoRivaroxaban91$108,269
JardianceEmpagliflozin42$39,835
BrilintaTicagrelor27$17,745
FarxigaDapagliflozin Propanediol27$15,339
Amiodarone Hcl254$6,969
Flecainide Acetate52$3,168
Atorvastatin Calcium343$3,158
Metoprolol Succinate271$2,839
ClopidogrelClopidogrel Bisulfate212$2,290
Carvedilol160$1,926
Losartan Potassium183$1,746
Metoprolol Tartrate294$1,589
Lisinopril157$1,148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11$366,343296 claims
NovartisEntresto$124$110,29888 claims
Johnson & JohnsonXarelto$37$108,26991 claims
Boehringer IngelheimJardiance$19$39,83542 claims
AstraZenecaBrilinta, Farxiga$100$33,08454 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 423 cardiovascular disease providers in Arizona.

Other cardiovascular disease in Apache Junction

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →